Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reboxetine + hyoscine for obstructive sleep apnoea
ACTRN12617001326381Phase 2Completed
- Sponsor
- Neuroscience Research Australia
- Start
- Nov 2017
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of reboxetine and scopolamine in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Neuroscience Research Australia. Primary endpoint: Sleep apnoea severity. Started Nov 2017; status: completed.
02
Drugs
reboxetinescopolamine
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ACTRN12617001326381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001326381.